Brii Biosciences Limited (BRIBF)
OTC Markets OTCPK · USD · Healthcare · Biotechnology
$0.13 (+0.00%) as of
Key statistics
- Market cap
- 93.82M
- EPS (TTM)
- -0.0400
- Dividend yield
- 0.00%
- 52-week range
- 0.1258 – 0.2459
- Beta
- 1.25
- Revenue (TTM)
- 34.85M
- Profit margin
- 0.00%
- Volume
- 4.15k
About Brii Biosciences Limited
Brii Biosciences Limited focuses on developing therapies for the treatment of infectious and central nervous system diseases in China and the United States. The company develops BRII-179, a recombinant protein-based HBV immunotherapeutic candidate; Elebsiran, an investigational subcutaneously administered HBV-targeting siRNA; and Tobevibart, an investigational subcutaneously administered HBV-neutralizing monoclonal antibody which are in Phase 2 of the development stage for functional cure of HBV for Hepatitis B; and BRII-732 that has completed Phase 1 clinical trial and BRII-753, which is in c for the treatment of HIV. It also develops Soralimixinfor the treatment of multi-drug resistant or extensive drug resistant (MDR/XDR) gram-negative bacterial infections, which has completed Phase 1; and Epetraborole for oral treatment for patients with treatment-refractory mycobacterium avium complex (MAC) lung disease. Brii Biosciences Limited was incorporated in 2017 and is headquartered in Beijing, China.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Beijing, China
- Employees
- 80
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.